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Objective: To evaluate the potential of ADAMTS-4 (aggrecanase -1) activity in synovial ﬂuid (SF) as a
biomarker of knee injury and joint disease.
Design: We have measured ADAMTS-4 activity in the synovial ﬂuid of 170 orthopaedic patients with
different degrees of joint pathology, using a commercial ADAMTS-4 ﬂuorescence resonance energy
transfer (FRET) substrate assay. Patients were classiﬁed at arthroscopy as (i) macroscopically normal, (ii)
with an injury of the meniscus, anterior cruciate ligament or chondral/osteochondral defects or (iii) with
osteoarthritis, and the inﬂuence of independent factors (age, patient group, effusion and synovial
inﬂammation) on ADAMTS-4 activity levels was assessed.
Results: In most patients (106/170) ADAMTS-4 activity was undetectable; ADAMTS-4 ranged from 0 to
2.8 ng/mL in synovial ﬂuid from patients with an injury, 0e4.1 ng/mL in osteoarthritic patients and 4.0
e12.3 ng/mL in patients with large effusions. Four independent variables each signiﬁcantly inﬂuenced
ADAMTS-4 activity in synovial ﬂuid (all P < 0.001): age (concordance ¼ 0.69), presence of osteoarthritis
(OA) (concordance ¼ 0.66), level of effusion (concordance ¼ 0.78) and inﬂammation
(concordance ¼ 0.68). Not only did effusion inﬂuence the amount of ADAMTS-4 activity most strongly,
but it also did this in an ordered manner (P < 0.001).
Conclusions: The main ﬁnding of this study is that ADAMTS-4 levels in synovial ﬂuid are most strongly
correlated with inﬂammation and severity of effusion in the knee. Further study is required to determine
if it could provide a useful tool to aid clinical diagnoses, indicate treatment, to monitor progression of
joint degeneration or OA or alternatively the success of treatment.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
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r Ltd and Osteoarthritis Research Spatients is suggested as being partly responsible for the slow pace
of innovation in developing novel, effective treatments for osteo-
arthritis1. Osteoarthritis (OA) of the knee can develop secondary to
several disorders or injury in the joint andmanifests as alteration of
the joint structure, with progressive degradation of any or all of the
tissues within it, such as cartilage, menisci and ligaments, as well as
inﬂammation of the synovium and changes to the subchondral
bone. Measuring biomarkers in ﬂuids proximal to the site of the
pathology, such as the synovial ﬂuid (SF) in the knee, can be both
more informative about the disease state in that particular joint and
more sensitive, by virtue of their higher concentration than, for
example, in blood or urine2,3.
The best candidates for biomarkers in OA are suggested to be
structural molecules or enzymes linked to cartilage, bone orociety International. This is an open access article under the CC BY-NC-ND license
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biochemical changes to articular cartilage following injury or in
degenerative joint diseases, such as OA, is degradation and loss of
aggrecan. Matrix metalloproteinases (MMPs) and aggrecanases (or
A Disintegrin And Metalloprotease with Thrombospondin motifS
(ADAMTS)) are the enzymes attributedwith degrading themajority
of the aggrecan. The most common ‘pathological’ ADAMTS-
generated cleavage site in the aggrecan core protein is between
the 392glutamate and the 393alanine bond in the interglobular
domain (reviewed in 5). Many studies have been undertaken to
develop and trial measuring the presence of these ‘neo-epitopes’
generated by enzyme activity to assess their potential as bio-
markers with an ARGS-aggrecan assay showing considerable
promise when measured in blood or synovial ﬂuid6.
ADAMTS-5 (aggrecanase-2) is the predominant member of the
ADAMTS family in mice models of degenerative joint disease or OA.
The situation in humans is less clear and ADAMTS-4 (aggrecanase-
1) is likely to be a signiﬁcant player5. In this study we have used a
commercially available assay that can detect ADAMTS-4 activity
independently of any contribution from ADAMTS-5. We have
measured the extent of ADAMTS-4 activity in synovial ﬂuid from a
cohort of heterogeneous patients, typical of those attending an
orthopaedic outpatient clinic with different degrees of joint pa-
thology, ranging frommacroscopically normal to end stage OA. Our
objective was to investigate if measuring ADAMTS-4 activity could
provide a useful tool to aid the clinician.
Method
Patient samples
Synovial ﬂuid was collected from patients presenting with
clinical symptoms who were undergoing a routine diagnostic
arthroscopy of the knee and consented to take part in this study
(99\61\RJ approved by Shropshire Research Ethics Committee).
Patients were classiﬁed into three groups according to their
appearance at arthroscopy as assessed by the treating surgeon:
(i) those with macroscopically normal knees and no obvious
abnormality,
(ii) those with injury of the meniscus, anterior cruciate ligament
or chondral/osteochondral lesions and
(iii) those with OA (i.e., with features, such as the presence of
osteophytes and fragmenting articular cartilage in one or
more compartments of the knee (Outerbridge Grade 37) or
exposed subchondral bone (Outerbridge Grade 4).
The presence of synovial inﬂammation was noted when the
synovium was more reddened, swollen and convoluted than one
would expect in a normal knee joint and the extent of joint effusion
(none, small, moderate or large) was also assessed, using the sweep
and patella tap tests8. A small effusion was recorded if the sweep
test was positive but the patella tap test negative, a moderate
effusion was recorded if the sweep and patella tap tests were
positive and a large effusion was recorded if sweep and patella tap
tests were negative due to over-distention of the joint with
effusion.
The synovial ﬂuid was collected by injecting 20 mLs of 0.9%
saline into the synovial cavity prior to arthroscopy; the knee was
ﬂexed and extended 20 times to allowmixing of the saline with the
joint ﬂuid. A needle was then reinserted into the knee and the
synovial ﬂuid aspirated; in the laboratory it was centrifuged for
15 min at 3000 g and the supernatant stored at 80C until use.
Plasma was collected at the same time and a dilution factor of
the synovial ﬂuid was obtained by measuring the ratio of urea inSF:plasma (normally ~0.9 SF:serum)9. Urea was measured with a
colorimetric assay QuantiChrom™ Urea assay Kit (BioAssay Systems
DIUR-500).
ADAMTS-4 activity
ADAMTS-4 activity was measured in SF with the Sensolyte™ 520
ADAMTS-4 assay kit (Anaspec Inc) which uses a substrate for
ﬂuorescence resonance energy transfer (FRET), 5-FAM and TAMRA
as the donoreacceptor pair. This acts as a substrate for active
ADAMTS-4, which cleaves it into two separate fragments resulting
in an increase of 5-FAM ﬂuorescence which can be monitored at
excitation and emission of 490 nm and 520 nm, respectively. The
ADAMTS-4 assay was carried out according to the manufacturer's
instructions. Fifty microlitres of each sample of SF lavage were
pipetted into wells of a 96-well black microplate (Costar®, Corning
Life Sciences). In addition, a range of concentrations (2e10 ng) of
human recombinant ADAMTS-4 were pipetted into other wells to
provide a standard curve to relate ADAMTS-4 activity in the SF
samples to ng/mL of enzyme. Therewas also awell containing assay
buffer only, to provide a substrate control. Fifty microlitres of 5-
FAM ﬂuorescence reference standards (70e2500 nM) were set up
to calibrate the plate reader and act as an indicator of the amount of
ﬁnal product of the enzymatic reaction. The substrate solution (5-
FAM/5-TAMRA) was added after pre-incubation at 37C and the
ﬂuorescence intensity was measured following 60 min incubation
at 37C. Relating the amount of ﬂuorescence intensity from each
sample to that of the standard curve obtained from the recombi-
nant ADAMTS-4 and multiplying it by the appropriate dilution
factor for each SF sample, calculated the amount of ADAMTS-4
protein in each sample.
Statistics
The lower limit of detection (LLOD) and lower limit of quanti-
ﬁcation (LLOQ) of ADAMTS-4 were calculated from the standard
deviation of blank samples and the slope of the calibration curve.
QQ-plots were used to assess the distribution of continuous vari-
ables; age was normally distributed but ADAMTS-4 level was not.
ADAMTS-4 levels were therefore summarised using medians and
quartiles and compared between groups using non-parametric
tests whereas parametric tests were used for age. Fisher's exact test
was used to compare distributions in categorical variables (e.g.,
presence of effusion by patient classiﬁcation). ADAMTS-4 levels
below the LLOD were classiﬁed as having 0 ng/mL of ADAMTS-4.
We used a censored or Tobit regression model10 to investigate the
inﬂuence of the various independent factors (age, patient group,
effusion and inﬂammation) on ADAMTS-4 levels, with the left limit
set at the LLOD. This method requires a normal distribution for
ADAMTS-4 levels, which was achieved by a logarithmic trans-
formation, and minimises potential bias from the presence of an
LLOD compared to traditionally used methods such as imputing
half the LLOD for values below the LLOD10,11. The association be-
tween the independent factors (e.g., disease/injury, effusion and
the presence of an inﬂamed synovium) and ADAMTS-4 levels was
assessed by the concordance c (a generalisation of the area under
the curve (AUC) of a receiver operating characteristic (ROC) curve)
and Nagelkerke's R2, with 95% conﬁdence intervals calculated on
the basis of 999 bootstrap samples.
All statistical analysis was performed using R vs 3.0.3 (The R
Foundation for Statistical Computing) using the packages “censReg”
and “rms”. A P-value of 0.05 or below was assumed to denote
statistical signiﬁcance. In cases of multiple pairwise tests, P-values
were adjusted using Holm's procedure to maintain the 0.05 alpha-
level.
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Samples were collected from 170 patients, presenting with
symptoms for varying times, ranging from 1 month to 16 years.
The mean age of the macroscopically normal group was 28.6
years (8.5SD; n ¼ 22), the injury group 33.2 years (10.3SD;
n ¼ 96) and the OA group 48.7 years (16.9SD; n ¼ 10). A number
of patients combined an injury and OA (mean age 48.9
years ± 11.6SD; n ¼ 31). Mean age differed signiﬁcantly between
patients with OA (alone or combined with injury) and those with
‘macroscopically normal’ joints (both P < 0.001) or injured joints
(both P < 0.001, all pairwise t-tests). Eleven patients were not
classiﬁed. Effusions were present in 6% of ‘normal’ joints, 40% of
those with injuries, 71% of those with OA and 64% of those with
injuries and OA. Effusions were less common in ‘macroscopically
normal’ joints than any of the other types (P < 0.05) but other-
wise the incidence rates did not differ between the groups
(P > 0.25, all pairwise Fisher's exact tests). Inﬂammation was
noted in the knee joints of 25% of patients categorised as
‘macroscopically normal’, 54% of the injury group, 67% of the OA
group and 83% of those with injuries and OA. These rates were
higher in joints with OA and injury compared to ‘normal’ jointsTable I
Univariable and multivariable predictors of ADAMTS-4 in synovial ﬂuid of the knee
n* Median ADAMTS-
4
ng/mL (IQR)
P-valuey Coefﬁcientz (
Univariable analysis
Age 170 0.08 (0.04e0
OA 159 <0.001
No 118 0.0 (0e0.3) 2.4 (1.2e3.6
Yes 41 1.3 (0e4.1)
Injury 160 0.10
None 32 0 (0e0)
Chondral 95 0 (0e2.2) 1.7 (0.2e3.3
Other 33 0 (0e2.8) 1.4 (0.4e3
Effusion 122 <0.001k
No 71 0.0 (0.0e0.0)
Small 28 0.0 (0.0e0.75) 1.8 (0.4e3.2
Moderate 14 1.7 (0.2e3.4) 3.6 (1.9e5.3
Large 9 8.5 (4.0e12.3) 5.4 (3.4e7.3
Inﬂammation 144 <0.001
No 62 0.0 (0.0e0.0)
Yes 82 0.2 (0.0e2.8) 2.4 (1.1e3.6
Multivariable analysis
Full model 104
Age
OA
Injury
Effusion
Inﬂammation
Reduced model 106
Age 0.05 (0.01e0
Effusion
No
Small 1.7 (0.4e3.0
Moderate 3.3 (1.7e4.8
Large 4.4 (2.6e6.2
Inﬂammation
No
Yes 1.8 (0.5e3.0
Notes (IQR: interquartile range; CI: conﬁdence intervals).
* Number of patients for each analysis, which vary due to data missingness.
y P-values from univariate non-parametric statistical analyses.
z Coefﬁcients from censored regression.
x P-values from censored regression.
k P-value from Jonckheere trend test.
¶ Concordance and Nagelkerke's R2 values for individual predictors in the full and redu
They are therefore NOT partial concordance or R2 coefﬁcients.or those with only injury (P < 0.05), otherwise no differences
were found (P > 0.09, all pairwise Fisher's exact tests).
The LLOD and LLOQ of the ADAMTS-4 assaywere 0.14 ng/mL and
0.41 ng/mL, respectively. In most patients ADAMTS-4 activity did
not reach detectable levels (106 out of 170). It was detectable in
only 5% of samples from the ‘normal’ group, in 33% of the injury
group, in 60% of the OA group and in 67% of the combined injury
and OA group. These rates were lower in the ‘normal’ group
compared to each of the three others (P < 0.03) and lower in the
injury group compared to the combined injury and OA group
(P ¼ 0.004), but otherwise no differences were found (P > 0.32, all
pairwise Fisher's exact tests). The measured level of ADAMTS-4
ranged between 0.2 and 34.9 ng/mL SF (with a mean dilution fac-
tor for the SF samples of 3.6 (±2.2, range 1.1e12.1)). The median
level of ADAMTS-4 was 0 ng/mL in the ‘normal’ group (with one
patient having a detectable amount of 0.3 ng/mL), 0 ng/mL in the
injury group (range 0e29.8, with 32 patients having detectable
levels), 1.2 ng/mL in the OA samples (range 0e11.5, with six patients
having detectable levels) and 1.3 ng/mL in the combined injury and
OA group (range 0e15.4, with 21 patients having detectable levels).
There was signiﬁcantly less ADAMTS-4 in the ‘normals’ than any of
the other three patient groups and the injury group had less than95% CI) Concordancec (95% CI) Nagelkerke'sR2 (95% CI) P-valuex
.13) 0.69 (0.62e0.78) 0.10 (0.03e0.19) <0.001
0.66 (0.59e0.73) 0.11 (0.04e0.22) <0.001
)
0.58 (0.52e0.65) 0.03 (0.00e0.12) 0.10
)
.3)
0.78 (0.69e0.86) 0.31 (0.17e0.49) <0.001
)
)
)
0.68 (0.60e0.76) 0.11 (0.03e0.24) <0.001
)
0.88 (0.83e0.96) 0.46 (0.36e0.66)
0.72¶ 0.13¶ 0.07
0.65 0.10 0.64
0.54 0.01 0.86
0.79 0.34 <0.001
0.70 0.15 0.04
0.88 (0.83e0.95) 0.46 (0.34e0.63)
.09) 0.72¶ 0.13¶ 0.02
0.79 0.34 <0.001
)
)
)
0.71 0.16 0.006
)
ced models are the univariable values when calculated using each model's dataset.
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ManneWhitney tests).
Further analysis was simpliﬁed by separating the patient group
qualiﬁer into two: having OA (No/Yes) and having an injury (No/
Chondral/Other; Table I). No signiﬁcant interaction effect of injury
and OA on ADAMTS-4 levels was found (P ¼ 0.13; Tobit regression),
justifying their further analysis as separately additive.
Four independent variables each signiﬁcantly inﬂuenced
ADAMTS-4 levels (all P < 0.001; Table I, univariable analysis),
namely age (concordance ¼ 0.69; Nagelkerke's R2 ¼ 0.10), having
OA (concordance ¼ 0.66; Nagelkerke's R2 ¼ 0.11), effusion level
(concordance ¼ 0.78; Nagelkerke's R2 ¼ 0.31) and presence of an
inﬂamed synovium (concordance ¼ 0.68; Nagelkerke's R2 ¼ 0.11).
Effusion had the best predictive value, with ADAMTS-4 levels rising
in an ordered fashionwith increased effusion (P < 0.001, Jonckheere
test; Fig. 1). In all, 14% of patients with no effusion, 36% of patients
with a small effusion, 71% with a moderate effusion and 89% of
those with a large effusion had detectable levels of ADAMTS-4. The
signiﬁcance levels from the univariable Tobit regression and con-
ventional non-parametric tests were in complete agreement
(Table I).
The Tobit regression allows simultaneous investigation of mul-
tiple factors. Using all variables (full model; Table I) suggested that
three independent variables simultaneously signiﬁcantly inﬂu-
enced ADAMTS-4 levels, namely age, level of effusion and having an
inﬂamed synovium (reduced model, Table I).Discussion
Several international efforts have been and are addressing the
challenge of developing reliable, sensitive and speciﬁc biomarkers
for OA. Examples are those by the European Society for Clinical
Aspects of Osteoporosis and Osteoarthritis (ESCEO)4 and the
Osteoarthritis Research Society International e Federal Drugs
Agency (OARSI-FDA) initiative (http://oarsi.org/education/oarsi-Fig. 1. Levels of ADAMTS-4 (ng/mL) activity as a function of effusion size, shown as a
boxplot. The thick horizontal lines represent the medians, the boxes represent upper
and lower quartiles and the fences indicate the range up to 1.5 times the interquartile
range below or above the lower or upper quartiles. Values higher than 1.5 times the
interquartile range above the upper quartile are shown as open circles. The LLOD of
0.14 ng/ml is shown as a horizontal line.resources/fnih-osteoarthritis-biomarkers-consortium-project).
Many groups have investigated the aggrecanase-generated neo-
epitope ARGS and assays are now available with great sensitivity12
(down to 0.025 pmol/mL6). This neoepitope can be measured not
only in SF, but also in serum, plasma and urine, although results are
less reliable in urine6,13. These assays, however, will not discrimi-
nate between the different forms of aggrecanase or ADAMTSs. The
assay used in the present study measured activity of ADAMTS-4
(aggrecanase 1), with negligible cleavage of the FRET substrate by
other members of the aggrecanase family, such as ADAMTS-1 and
ADAMTS-5. Another ADAMTS-4 assay, using a ﬂuorescent ‘turn-on’
peptide conjugated to gold nanoparticles, demonstrated differen-
tial levels in acute and chronic joint injuries14.
Our data suggests that effusion level, presence of synovial
inﬂammation and age are the strongest determinants of level of
ADAMTS-4, with injury or OA being less important. Mechanical
loading is known to inﬂuence protease production, with the type of
load switching production between MMPs and aggrecanases, e.g.,
in rat intervertebral disc cells15. In amurinemodel of OA it has been
shown that gene expression of proteases, including ADAMTS-4 and
-5, is both rapid and highly mechanosensitive16. This could explain
the particularly strong relationship whichwe saw between effusion
(and so swelling and increased pressure) in the joint and levels of
ADAMTS-4 activity. Since ADAMTS-5 activity has not been assessed
in the present study, it would be very interesting to measure this in
the same or similar patient groups to determine if it also is
increased with effusion.
The relative levels of MMP and aggrecanase production in a joint
may be important not only to how the joint tissues degrade but also
to the individual's ability to heal that injury and to their likelihood
of developing OA. The DBA/1 strain of mice, which shows superior
healing of injuries compared to the C57BL/6 strain, have less
aggrecanase- but more MMP-induced aggrecan degradation than
the C57BL/6 mice. In addition, the DBA/1 mice did not go on to
develop subsequent signs of OA seen in the C57BL/6 mice17.
If ADAMTS-4 proves useful as a biomarker, further information
on the aetiopathogenesis of degenerative joint disease(s) may be
possible by measuring a differentially spliced variant of ADAMTS-4
which appears to be produced predominantly by synovial cells,
particularly in OA18. Certainly differentiating the tissue source is
important for biomarkers as ADAMTS-4 has been shown to be
involved in atherosclerosis and is produced by monocytes from
patients with acute coronary syndrome19. In addition, identiﬁca-
tion that ADAMTS-4 is a key player can help identify patients who
might beneﬁt from speciﬁc ADAMTS-4 inhibitors which are being
developed. In terms of the BIPED classiﬁcation of biomarkers20
(Burden of disease, Investigative, Prognostic, Efﬁcacy of interven-
tion or Diagnostic), evidence from this study suggests that
ADAMTS-4 may prove useful for investigating the aetiopatho-
genesis of disease, making a diagnosis of joint effusion or inﬂam-
mation and perhaps assessing the burden of the disease.
Conversely, our results also suggest that the extent of joint effusion
might serve as a proxy for ADAMTS-4 levels in the joint ﬂuid. The
low concordance and large inﬂuence of confounding factors sug-
gest ADAMTS-4 is unlikely to be suitable for OA diagnosis.
There are, of course, several limitations to this study. One such is
the way we related the relative ﬂuorescent units created by the
ADAMTS-4 in the SF samples to protein levels (ng/mL). We made
the assumption that the kinetic curve would be the same for the
recombinant ADAMTS-4 as it would be for the ADAMTS-4 in the
biological samples, which of course it may not be. Different trun-
cations and portions of the enzyme give different kinetics18. Vari-
ation in ADAMTS-4 structure, such as has been seen in OA joints,
warrants further investigation in this matter in future studies.
Another limitation is that we have only assessed ADAMTS-4 activity
S. Roberts et al. / Osteoarthritis and Cartilage 23 (2015) 1622e16261626levels in comparison to a limited number of variables and obser-
vations and there are always more which could be made. For
example, it would be interesting to determine if there was a rela-
tionship with the duration of patients' symptoms. A further prob-
lemwith the study is missing data. Ideally, we would have full data
on all patients but as in most ‘real world’ clinical studies this was
not possible and for some patients information is partly lacking
(e.g., 11 patients (6.5%) were not classiﬁed by the surgeon into 1 of
the 3 categories at the time of the arthroscopic assessments). We
believe that this data is missing completely at random as a conse-
quence of busy clinics and therefore ‘missingness’ should not add
bias to the assessments.
In conclusion, identiﬁcation and validation of reliable, sensitive
biomarkers for injured or degenerate joints remain important
goals, not only for patient diagnosis and prognosis, but also for
furthering our understanding of disease progression and indicating
therapies which can be applied at a stage when the disease can be
alleviated or modulated. We believe that measuring the level of
ADAMTS-4 shows promise as a potentially useful biomarker and is
worthy of further study.
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